Logo

OMER

Omeros Corporation

OMER

Omeros Corporation • NASDAQ
$9.69 ▲ 0.62% (+0.06)
Market Cap $686.96 M
52w High $13.60
52w Low $2.95
Dividend Yield 0%
P/E -4.8
Volume 594.03K
Outstanding Shares 70.89M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $26.392M ▲ $-30.917M ▼ 0% $-0.47 ▼ $-15.585M ▲
Q2-2025 $0 $22.061M ▼ $-25.424M ▲ 0% $-0.43 ▲ $-32.154M ▲
Q1-2025 $0 $34.969M ▼ $-33.46M ▼ 0% $-0.58 ▼ $-33.622M ▼
Q4-2024 $0 $35.359M ▼ $-31.358M ▲ 0% $-0.54 ▲ $-33.063M ▼
Q3-2024 $0 $35.407M $-32.232M 0% $-0.56 $-32.824M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $36.085M ▲ $185.706M ▼ $406.184M ▼ $-220.478M ▲
Q2-2025 $28.744M ▼ $200.569M ▼ $429.254M ▼ $-228.685M ▼
Q1-2025 $52.411M ▼ $235.161M ▼ $448.714M ▼ $-213.553M ▼
Q4-2024 $90.132M ▼ $277.079M ▼ $459.688M ▼ $-182.609M ▼
Q3-2024 $123.157M $313.335M $467.507M $-154.172M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-30.917M ▼ $-18.473M ▲ $-6.861M ▼ $25.825M ▲ $491K ▲ $-18.484M ▲
Q2-2025 $-25.424M ▲ $-21.938M ▲ $21.297M ▼ $-1.716M ▲ $-2.357M ▼ $-21.951M ▲
Q1-2025 $-37.565M ▼ $-35.841M ▼ $38.541M ▲ $-1.839M ▲ $861K ▼ $-35.882M ▼
Q4-2024 $-31.358M ▲ $-28.98M ▲ $34.954M ▼ $-4.095M ▲ $1.879M ▲ $-29.006M ▲
Q3-2024 $-32.232M $-32.058M $36.038M $-4.579M $-599K $-32.059M

Five-Year Company Overview

Income Statement

Income Statement Omeros is still very much a development‑stage company from an income perspective. It has essentially no recurring product revenue and has been funding itself through deals and other non-recurring sources. Core operations run at a steady loss, reflecting ongoing R&D and overhead without commercial sales to offset those costs. The occasional year of reported profit appears driven by one‑time transactions rather than a sustainable business model. Overall, the income statement shows a company reliant on future drug approvals or additional partnerships to move toward consistent profitability.

Balance Sheet

Balance Sheet The balance sheet shows a small asset base, limited cash, and a meaningful amount of debt. Shareholders’ equity has swung from slightly positive back to negative, which means obligations are heavy relative to the asset pool. This structure gives the company a thin financial cushion and raises sensitivity to setbacks or delays. While not unusual for a clinical‑stage biotech, it leaves Omeros dependent on external financing, milestone payments, or partnership proceeds to maintain operations and advance its pipeline.

Cash Flow

Cash Flow Cash flow is dominated by cash outflows tied to R&D and overhead, with only a brief period of positive cash flow that likely reflected a specific transaction rather than normal business activity. Free cash flow is consistently negative because there is no operating cash inflow and little to no capital spending. In practical terms, the company is burning cash and will need continued access to capital markets, partnerships, or milestone payments to support its programs until it can generate recurring commercial revenue.

Competitive Edge

Competitive Edge Omeros has carved out a scientific niche in the complement system, particularly the lectin and alternative pathways, which differentiates it from many peers. Its lead asset, narsoplimab, targets a specific enzyme in a way that aims to preserve key immune functions, providing a potentially meaningful clinical and safety edge. Strong intellectual property around MASP‑2 and a broad set of programs across complement, oncology, infectious disease, and CNS disorders add to its strategic position. However, the company is small, faces competitors with far greater resources in immunology and rare disease, and is heavily dependent on one late‑stage asset and a few key platforms for its long‑term standing.

Innovation and R&D

Innovation and R&D Innovation is the core strength here. Omeros is pursuing first‑in‑class approaches in complement biology, with narsoplimab as the flagship and OMS1029 as a long‑acting follow‑on. The sale of its MASP‑3 program to a major pharmaceutical company both validates the science and brings in non‑dilutive capital. Beyond complement, the T‑CAT anti‑infective platform, immuno‑oncology efforts, GPCR discovery engine, and a program in addictive disorders point to a diversified, idea‑rich R&D engine. The flip side is that most of these programs are early stage, technically complex, and expensive to prosecute, so the scientific potential is high but paired with substantial development and execution risk.

Summary

Omeros is a science‑driven biotechnology company with a focused expertise in complement biology and a surprisingly broad set of experimental platforms for its size. Financially, it remains a pre‑revenue, loss‑making business with a thin balance sheet, ongoing cash burn, and reliance on transactions, debt, or equity raises to fund operations. Strategically, the company’s future is tightly linked to the regulatory outcome for narsoplimab and its ability to convert a deep pipeline into approved products or attractive partnerships. The combination of strong innovation and weak current financial strength makes this a high‑risk, high‑uncertainty profile where clinical and regulatory milestones are likely to drive large swings in outlook over the next several years.

NEWS

November 13, 2025 · 4:11 PM UTC

Omeros Corporation Reports Third Quarter 2025 Financial Results

Read more

November 11, 2025 · 8:30 AM UTC

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025

Read more

October 16, 2025 · 8:30 AM UTC

Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group

Read more

October 15, 2025 · 8:30 AM UTC

Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros' clinical-stage MASP-3 inhibitor zaltenibart (OMS906)

Read more

September 2, 2025 · 8:45 AM UTC

Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program

Read more